We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.29 | 0.66% | 43.99 | 44.33 | 43.685 | 43.93 | 12,104,157 | 01:00:00 |
By Matt Grossman
Bristol Myers Squibb Co.'s deucravacitinib drug for plaque psoriasis achieved positive results in a pair of Phase 3 trials, the drug maker said Friday.
In the studies, adults with moderate to severe plaque psoriasis took 6 mg of the oral drug once a day. In both trials, more than 50% of patients achieved at least a 75% improvement from baseline on a psoriasis metric after 16 weeks, compared with under 15% among patients who got a placebo and 35% to 40% among patients who took Otezla, another psoriasis drug. The share of patients with a positive response improved after eight more weeks, and most of those patients maintained their positive response in the 52nd week of treatment.
In the studies, deucravacitinib also performed better than placebo and Otezla in helping patients achieve sPGA 0/1 response, another psoriasis metric based on a physician's assessment.
The drug was well tolerated, Bristol added.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
April 23, 2021 10:35 ET (14:35 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions